Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iodine-124 evuzamitide
- Development stage
- Unknown
- Lead developer
- Attralus
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Iodine (124I) evuzamitide (AT-01) is an investigational pan-amyloid radiopharmaceutical developed by Attralus for the diagnosis and management of systemic amyloidosis. It consists of a synthetic 45-amino-acid peptide (p5+14) that binds to amyloid fibrils and hypersulfated heparan sulfate glycans through electrostatic interactions. Radiolabeled with the positron-emitting radionuclide iodine-124, it is used as a PET/CT imaging agent to detect various types of amyloid deposits, including AL and ATTR, across multiple organs such as the heart, kidney, liver, and spleen. It has received FDA Breakthrough Therapy Designation for imaging cardiac amyloidosis and is currently in Phase 3 clinical trials.
- Other names
- iodine (124I) evuzamitide124I-evuzamitideiodine-124 evuzamitideiodine124 evuzamitideiodine 124 evuzamitide
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))
Beyond the preview
Go deeper on iodine-124 evuzamitide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iodine-124 evuzamitide.